AMRX // Amneal Pharmaceuticals Inc.

DES <GO> NASDAQ CIK 0001723128 ↗

Health Care • Biotechnology: Pharmaceutical Preparations

$21.35 ▲ +0.21 (+0.99%)

MKT CAP: $7.44B • VOL: 4.40M

52W L $11 52W H $22

ALTMAN Z

3.83 SAFE

PIOTROSKI

9 / 9

AMRX // ROARABLE RATING & 5-PILLAR RQD CONFIDENCE 02:00 EST DETERMINISTIC ENGINE

PRIOR: RQD 65/100 [C] (+0 PT) • UNCHANGED AS OF 2026-11-01

ROARABLE C

RQD CONFIDENCE

65 / 100 +0D

5 X 20-PT QUANT PILLARS

E 0 D 35 C 59 B 70 A 86+

Roarable Hold — Fair / Balanced Risk-Reward

01 MASSIVE / SEC XBRL

Forensic Fundamentals

14 / 20

SOLID

FCF +11% vs NI +161.6% • ROIC-WACC +6.2% • Z 3.83

02 OPRA GEX + SEC 13F

Whale & Options Flow

[LOCKED] FLAGGED

UNLOCK BELOW TO REVEAL

03 SEC FORM 4 (90D)

Insider Conviction

[LOCKED] FLAGGED

UNLOCK BELOW TO REVEAL

04 FRED 90D r-MATRIX

Macro Regime Fit

13 / 20

SOLID

TAILWIND • r(10Y)=+0.00 (+23bp) • r(OAS)=+0.00

05 10-K REDLINE AUDIT

Forensic 10-K Risk

16 / 20

STRONG

20 BASE - 4 DEDUCT • 0 CRIT / 0 MED • STABLE

ALERT

Why did AMRX's Whale & Options Flow & Insider Conviction sub-score just flash a warning? Enter your email to unlock the full 5-Pillar Rating Breakdown + get instant alerts whenever AMRX is Upgraded or Downgraded.

SIG <GO> CROSS-FEED TRIANGULATION // PROPRIETARY ANOMALY ENGINE (1 ACTIVE ON AMRX)

STAGE 2 DETERMINISTIC Z-SCORE + STAGE 3 GEEK DESK BRIEF ALL MARKET ANOMALIES <SIG>

▼ BEARISH // F-RATED EARNINGS MIRAGE // ACCRUAL WATCHSIFTER 02 // ACCRUAL & RECEIVABLES FORENSICS

SEVERITY: 82/100 Z-SCORE: +2.31σ

AMRX Accounting Gap: Net Income (+161.6%) Outpaced OCF (+15.2%) With +2.2% Working-Capital Build

CASH CONVERSION GAP

+146.4% (NI vs OCF)

RECEIVABLES / WC BLOAT

+2.2% VS REV

60D C-SUITE FORM 4 SALES

0 OPEN-MKT DUMPS

[GEEK DESK FORENSIC NOTE // SEC XBRL × FORM 4 CROSS-CHECK]

SEC EDGAR XBRL CompanyFacts10-K/10-Q Working Capital ScheduleSEC Form 4 Executive Sales

SEC EDGAR XBRL triangulation on Amneal Pharmaceuticals Inc. (AMRX) exposes a +146.4% Cash Conversion Gap as YoY Net Income growth (+161.6%) diverged from Operating Cash Flow growth (+15.2%). Non-cash current assets and receivables expanded +2.2% relative to top-line revenue growth. Monitor upcoming 10-Q cash realization closely for accrual mean-reversion.

AMRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +67.13%📐 HORIZONTAL RANGE

2026-10-30O $21.51H $21.68L $21.27C $21.51VOL 2.77M

RES: $22.67SUP: $16.63SMA50: $19.12SMA200: $15.74

AMRX // INSTITUTIONAL BULL VS. BEAR FORENSIC DEBATE

UNDERWEIGHT CONVICTION: 29/100

BEAR 0

100 BULL

Amneal Pharmaceuticals Inc. (AMRX) exhibits 36.9% gross margins and 14.1% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 21.4x enterprise multiple and 7.2% implied options volatility.

▲ INSTITUTIONAL BULL THESIS (LONG)

01. Operating Leverage & Capital Efficiency Moat

Sustained 36.9% gross profitability converts into 13.1% operating margin and 14.1% ROIC, outpacing sector cost of capital.

ROIC: 14.1% // GM: 36.9%

02. Top-Line Expansion & Cash Conversion

YoY revenue trajectory of +8.0% paired with 3.63% free cash flow yield supports self-funded R&D and capital return.

REV YOY: +8.0% // FCF YLD: 3.63%

03. Balance Sheet Solvency & Forensic Quality

Altman Z-Score of 3.83 and Piotroski F-Score of 9/9 indicate low near-term refinancing stress.

ALTMAN Z: 3.83 // F-SCORE: 9/9

▼ INSTITUTIONAL BEAR THESIS (SHORT / RISK)

01. Multiple Compression & Duration Sensitivity

Trading at 103.2x trailing P/E (96.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.

P/E: 103.2x // EV/EBITDA: 21.4x

02. Options Skew & Event Volatility Risk

Options market prices a ±7.2% implied move with a 0.75 put/call ratio around $21.00 max pain.

IMPL MOVE: ±7.2% // P/C: 0.75

03. Competitive Margin & CapEx Cycle Pressure

Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 2.4% net margins.

NET MARGIN: 2.4% // D/E: 0.85x

KEY CATALYST // Upcoming 10-Q/10-K XBRL margin progression, guidance revision vs 96.0x forward consensus, and institutional 13F positioning.

MACRO REGIME // Monitor US 10Y Real Yields (DFII10) and High-Yield Credit Spreads (OAS) for beta-adjusted multiple impact (Beta 1.08).

FORM 4 & 13F FLOW OPEN OWN <GO>

FILER	SIDE	$ VALUE
INSPECT FULL OWNERSHIP LEDGER IN OWN <GO>

UNUSUAL OPTIONS TAPE OPEN OPT <GO>

STRIKE / EXP	TYPE	PREMIUM
INSPECT GEX & CHAIN IN OPT <GO>

KEY VALUATION & PROFITABILITY RATIOS XBRL FA <GO>

TRAILING P/E 103.2x

FORWARD P/E 96.0x

EV / EBITDA 21.4x

FCF YIELD 3.63%

GROSS MARGIN 36.9%

OPERATING MARGIN 13.1%

NET MARGIN 2.4%

ROIC % 14.1%

REV GROWTH YOY +8.0%

DILUTED EPS TTM $0.21

DEBT / EQUITY 0.85x

DIVIDEND YIELD 0.00%

RSI-14 MOMENTUM 67.7

5Y EQUITY BETA 1.08

FRED MACRO SENSITIVITY (PEARSON r) ECST <GO>

MACRO CORRELATION CALIBRATION ACTIVE BELOW.

FRED MACRO REGIME STRESS-TEST SIMULATOR // AMRXPEARSON R VARIANCE ENGINE

01 // SELECT FEDERAL RESERVE & CREDIT SHOCK SCENARIO

02 // POSITION NOTIONAL EXPOSURE

HEADLINE STRESS SCORE

75/100SEVERE DRAWDOWN PRESSURE

PRIMARY FACTOR EXPOSURE

DFII10 // -0.61 r

Latest: 2.08%

EST. DIRECTIONAL MOVE

-8.50%

Implied Px: $19.54

EST. DOLLAR VARIANCE

-$4,248

On $50,000 Notional

[LOCKED // MULTI-FACTOR DRAWDOWN HEDGE & MACRO TRIGGER ALERT]

Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for AMRX & activate live FRED threshold breach alerts.

HEAD-TO-HEAD PEER COMPARISONS COMP <GO>

AMRX VS LLY

MARGINS ROIC VALUATION

AMRX VS JNJ

MARGINS ROIC VALUATION

AMRX VS ABBV

MARGINS ROIC VALUATION

AMRX VS UNH

MARGINS ROIC VALUATION